Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Antiviral therapy is urgently needed to combat the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The protease inhibitor camostat mesylate inhibits SARS-CoV-2 infection of lung cells by blocking the virus-activating host...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv
Main Authors: Hoffmann, Markus, Hofmann-Winkler, Heike, Smith, Joan C., Krüger, Nadine, Sørensen, Lambert K., Søgaard, Ole S., Hasselstrøm, Jørgen Bo, Winkler, Michael, Hempel, Tim, Raich, Lluís, Olsson, Simon, Yamazoe, Takashi, Yamatsuta, Katsura, Mizuno, Hirotaka, Ludwig, Stephan, Noé, Frank, Sheltzer, Jason M., Kjolby, Mads, Pöhlmann, Stefan
Format: Artigo
Language:Inglês
Published: Cold Spring Harbor Laboratory 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418737/
https://ncbi.nlm.nih.gov/pubmed/32793911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.08.05.237651
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items